Pole3: A Potential Drug Target and Biomarker (G54107)

Target Name: POLE3

NCBI ID: G54107

POLE3

Pole3: A Potential Drug Target and Biomarker

Pole3 is a protein that is expressed in various tissues and organs, including the brain, heart, and gastrointestinal tract. It is a key regulator of cell growth and differentiation, and is involved in the development and maintenance of tissues and organs. In recent years, research has focused on the potential drug targets and biomarkers associated with Pole3.

One of the key features of Pole3 is its role in cell signaling. Pole3 is a transcription factor that regulates the expression of genes involved in cell signaling pathways, including the TGF-β pathway. This pathway is involved in the development and maintenance of tissues and organs, and is a key factor in the development of cancer.

In addition to its role in cell signaling, Pole3 is also involved in the regulation of cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs, and is a critical factor in the development and maintenance of these structures. Pole3 is involved in the regulation of cell adhesion by controlling the expression of genes involved in cell adhesion processes.

The potential drug targets associated with Pole3 include those involved in cell signaling and cell adhesion. Some of these targets are known to be involved in the development and maintenance of cancer, and may be potential targets for anti-cancer drugs. For example, research has suggested that Pole3 may be a potential target for the anti-cancer drug doxorubicin, which is used to treat various types of cancer.

In addition to its potential as a drug target, Pole3 may also be a useful biomarker for the diagnosis and monitoring of various diseases. For example, research has suggested that Pole3 may be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, Pole3 has been shown to be involved in the development and progression of various types of cancer, including breast, ovarian, and colorectal cancers.

Overall, the potential drug targets and biomarkers associated with Pole3 are an exciting area of research, and have the potential to lead to new treatments and therapies for a variety of diseases. Further studies are needed to fully understand the role of Pole3 in cell signaling and cell adhesion, as well as its potential as a biomarker for disease.

Protein Name: DNA Polymerase Epsilon 3, Accessory Subunit

Functions: Accessory component of the DNA polymerase epsilon complex (PubMed:10801849). Participates in DNA repair and in chromosomal DNA replication (By similarity). Forms a complex with CHRAC1 and binds naked DNA, which is then incorporated into chromatin, aided by the nucleosome-remodeling activity of ISWI/SNF2H and ACF1 (PubMed:10801849). Does not enhance nucleosome sliding activity of the ACF-5 ISWI chromatin remodeling complex (PubMed:14759371)

The "POLE3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POLE3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets